What Curium does

Curium is a privately-held pharmaceutical manufacturer specializing in radiopharmaceuticals for nuclear medicine, operating as part of the Curium Pharma corporation. The company develops both diagnostic and therapeutic radiopharmaceuticals, with a notable focus on prostate cancer through its proprietary PSMA-I&T platform. Its core products include 64Cu-PSMA-I&T, a PET imaging agent for prostate cancer diagnosis currently completing a registrational Phase 2 trial in Japan, and 177Lu-PSMA-I&T, a therapeutic counterpart intended for metastatic castration-resistant prostate cancer as part of a theranostic approach pairing diagnostics and targeted radionuclide therapy.

The company's technology foundation rests on radiochemistry expertise, isotope handling, and peptide-based targeting of cancer biomarkers such as prostate-specific membrane antigen (PSMA). Through strategic partnerships with Curasight A/S (uTRACE diagnostic platform, up to USD 70 million in potential milestones), PeptiDream Inc., and PDRadiopharma Inc. (Japan market access), Curium is building a globally distributed development and commercialization infrastructure spanning Europe, Japan, and North America. The firm operates as a wholly-owned subsidiary structure with regional entities including Curium Finland Oy (established 2017, Helsinki).

Curium generates revenue through direct B2B supply relationships with hospitals, clinics, and nuclear medicine departments, distributing radiopharmaceutical products through regulated medical supply chains that require specialized handling and compliance. Treatment pricing for radioligand therapies in this category ranges from approximately USD 95,000 in the EU to over USD 200,000 in the US per treatment episode, based on industry benchmarks. The company serves the broader oncology and nuclear medicine sectors, with primary emphasis on prostate cancer patients and the healthcare providers treating them, while pursuing additional indications through its partnership-driven pipeline.

Name

Curium

Legal name

Curium Finland Oy

Website

https://mapmedical.fi

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Curium is a private radiopharmaceutical manufacturer developing diagnostic and therapeutic nuclear medicines for oncology, with a primary focus on prostate cancer theranostics. It serves hospitals and nuclear medicine departments globally through direct B2B supply partnerships across Europe, Japan, and North America.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)

Keywords

• Radiopharmaceutical manufacturing
• Nuclear medicine products
• PET imaging agents
• Radioligand therapy
• Cancer diagnostics

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Distribution channels1 record

Marketing channels2 records

Core offering

Curium manufactures and supplies radiopharmaceutical products for nuclear medicine, including diagnostic PET imaging agents and therapeutic radioligand therapies. Its core pipeline targets prostate cancer through a theranostic approach pairing 64Cu-PSMA-I&T (PET diagnostic) with 177Lu-PSMA-I&T (therapeutic). Products are supplied directly to hospitals, clinics, and nuclear medicine departments via a regulated medical supply chain.

Product overview

Curium is the world leader in radiopharmaceuticals, offering a diverse product portfolio in nuclear medicine. The company develops both diagnostic and therapeutic radiopharmaceuticals, including 64Cu-PSMA-I&T (PET diagnostic agent for prostate cancer) and 177Lu-PSMA-I&T (therapeutic counterpart), which are part of a theranostic approach targeting prostate-specific membrane antigen (PSMA). Curium serves healthcare providers with products for cancer diagnostics and targeted radionuclide therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• 64Cu-PSMA-I&T A PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), developed for prostate cancer diagnosis and staging in patients with unfavorable intermediate to very high-risk disease. Sold to hospitals and nuclear medicine departments through direct supply relationships.
• 177Lu-PSMA-I&T A therapeutic radiopharmaceutical using lutetium-177, developed as the therapeutic counterpart to 64Cu-PSMA-I&T for treatment of metastatic castration-resistant prostate cancer as part of a theranostic pairing.

Quantifiable outcome

• Results expected to support future regulatory submission in Japan for 64Cu-PSMA-I&T

Segments1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Curasight A/ScoreStrategic or Co-development PartnerStrategic collaboration with Copenhagen-based clinical-stage theranostic company Curasight A/S for the Phase 2 uTRACE prostate cancer trial. The partnership could result in up to USD 70 million in milestone payments for Curasight. Curium Inc. conducts the trial which investigates a diagnostic platform for better prostate cancer diagnosis and risk stratification.
• PeptiDream Inc.coreStrategic or Co-development PartnerCollaboration with Tokyo-based PeptiDream Inc. for the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T in Japan. PeptiDream brings proprietary peptide discovery technology and local regulatory expertise for Japanese market access.
• PDRadiopharma Inc.coreStrategic or Co-development PartnerPDRadiopharma Inc., a wholly owned subsidiary of PeptiDream, is a key partner in the Japan clinical trial of 64Cu-PSMA-I&T. The company focuses on radiopharmaceutical development and commercialization in the Japanese market.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Novartis: Novartis develops and commercializes Pluvicto (177Lu-PSMA-617), the first FDA-approved PSMA-targeted radioligand therapy for mCRPC. Directly competes with Curium's 177Lu-PSMA-I&T in the same therapeutic indication and shares the radiopharmaceutical development paradigm.
• NorthStar Medical Radioisotopes: NorthStar produces medical radioisotopes including Mo-99/Tc-99m using non-uranium production methods. Comparable to Curium's radioisotope production capability for nuclear medicine supply chain.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with PYLARIFY (18F-DCFPyL), a PSMA-targeted PET diagnostic for prostate cancer. Competes directly with Curium's 64Cu-PSMA-I&T in the PSMA imaging market and operates the same theranostic-aligned strategy.
• Curium Pharma (parent): Curium Pharma is the global parent entity of Curium Finland Oy, operating the broader radiopharmaceutical manufacturing business across multiple geographies. Directly comparable as the same corporate platform at the parent level.
• Telix Pharmaceuticals: Telix develops Illuccix (68Ga-PSMA-11) for PSMA PET imaging and is advancing TLX591 (177Lu-rosopatamab) for PSMA RLT, positioning it as a direct theranostic competitor to Curium's PSMA-I&T platform in prostate cancer.

Broad incumbents

• GE HealthCare: GE HealthCare operates a broad radiopharmaceutical and molecular imaging portfolio including PET tracers and the PETNET Solutions radiopharmacy network. Overlaps with Curium's diagnostic imaging business as a larger incumbent with diversified offerings across nuclear medicine.
• Bayer: Bayer markets Xofigo (223Ra) for prostate cancer bone metastases and has an active radiopharmaceutical pipeline. As a broad incumbent with significant oncology commercial infrastructure, Bayer is comparable to Curium in radiopharmaceutical manufacturing scale and oncology focus.
• Bracco Imaging: Bracco is a global leader in diagnostic imaging agents including iodinated and gadolinium-based contrast media and is expanding into radiopharmaceuticals. Comparable as a broad incumbent in imaging-related pharmaceutical manufacturing serving hospitals and imaging centers.

Others

• Cardinal Health Nuclear Pharmacy Services: Cardinal Health operates the largest U.S. radiopharmacy distribution network supplying unit-dose radiopharmaceuticals to hospitals. Relevant as a downstream channel partner and supply chain comparable for Curium's hospital distribution model.

Emerging players

• Curasight A/S: Curasight is a clinical-stage theranostic company developing the uTRACE platform for prostate cancer diagnosis and is a strategic partner of Curium (up to USD 70M in milestones). Partially overlaps with Curium's theranostic strategy as an emerging specialist in the same disease area.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/curiumpharma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curium